曲美他嗪联合比索洛尔治疗慢性心力衰竭合并慢性阻塞性肺疾病患者的效果：系统评价和荟萃分析方案。
Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis.
机构信息
Department of Respiratory Medicine, Changyi People's Hospital.
Department of Respiratory Medicine, Changle People's Hospital.
出版信息
Medicine (Baltimore). 2021 Apr 16;100(15):e25491. doi: 10.1097/MD.0000000000025491.
BACKGROUND
To the best of our knowledge, there is no study that has conducted a review investigating the clinical efficacy and safety of bisoprolol combined with trimetazidine on chronic heart failure (CHF) patients with chronic obstructive pulmonary disease (COPD). Therefore, in order to provide new evidence-based medical evidence for clinical treatment, we undertook a systematic review and meta-analysis to assess the effectiveness and safety of bisoprolol combined with trimetazidine on CHF patients with COPD.
METHODS
Seven electronic databases including Web of Science, Embase, PubMed, Wanfang Data, Scopus, Science Direct, Cochrane Library will be searched in April 2021 by 2 independent reviewers. For search on PubMed, the following search terms will be used: "trimetazidine, bisoprolol, chronic heart failure, chronic obstructive pulmonary disease." In order to achieve a consistency of extracted items, the data extractors will extract data from a sample of eligible studies. The outcomes include all-cause mortality and hospitalization for cardiac or/and respiratory causes; left ventricular structure and function; and functional scores. Review Manager software (v 5.4; Cochrane Collaboration) will be used for the meta-analysis. Two independent reviewers will assess the risk of bias of the included studies at study level. Any disagreements will be discussed and resolved in discussion with a third reviewer.
RESULTS
The results of our review will be reported strictly following the PRISMA criteria.
CONCLUSIONS
The review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings.
OSF REGISTRATION NUMBER
10.17605/OSF.IO/ZWPRB.
背景
据我们所知，目前尚无研究对合并慢性阻塞性肺疾病（COPD）的慢性心力衰竭（CHF）患者使用比索洛尔联合曲美他嗪的临床疗效和安全性进行评估。因此，为了为临床治疗提供新的循证医学证据，我们进行了系统评价和荟萃分析，以评估比索洛尔联合曲美他嗪对合并 COPD 的 CHF 患者的有效性和安全性。
方法
2 名独立评审员于 2021 年 4 月在七个电子数据库中进行检索，包括 Web of Science、Embase、PubMed、万方数据、Scopus、Science Direct 和 Cochrane Library。在 PubMed 上进行搜索时，将使用以下搜索词：“曲美他嗪、比索洛尔、慢性心力衰竭、慢性阻塞性肺疾病”。为了确保提取项目的一致性，数据提取人员将从合格研究的样本中提取数据。结果包括全因死亡率和因心脏或/和呼吸原因住院；左心室结构和功能；以及功能评分。将使用 Review Manager 软件（v5.4；Cochrane 协作网）进行荟萃分析。两名独立评审员将在研究水平上评估纳入研究的偏倚风险。任何分歧将通过与第三名评审员进行讨论和解决。
结果
我们的综述结果将严格按照 PRISMA 标准报告。
结论
该综述将通过提供有力的证据和改善临床实践指导，为现有文献增添内容。
OSF 注册号：10.17605/OSF.IO/ZWPRB。
Zotero 插件